Clinical Challenge: CLL in Adolescents and Young Adults
Chronic lymphocytic leukemia (CLL) is typically a disease of the elderly, but not exclusively. It does occasionally strike younger patients.
In the U.S., the median age of…
Browsing Tag
CLL
Clinical Challenge: Risk of Tumor Lysis Syndrome With Venetoclax in CLL
Venetoclax (Venclexta), a potent oral BCL2 inhibitor, is increasingly being used for the treatment of patients with chronic lymphocytic leukemia (CLL). However, its efficacy at…
Fixed-Duration, All-Oral Regimen Slows CLL Progression
Older patients with newly diagnosed chronic lymphocytic leukemia (CLL) had an almost 80% reduction in the risk of disease progression or death with a fixed-duration, all-oral…
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL
Treatment with the second-generation Bruton tyrosine kinase (BTK) inhibitor led to better oncologic outcomes compared with ibrutinib (Imbruvica) for patients with relapsed/refractory…
Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patients
In a head-to-head trial of Bruton's tyrosine kinase inhibitors, acalabrutinib (Calquence) demonstrated similar efficacy to ibrutinib (Imbruvica), but with less cardiotoxicity, in…